Transcenta Holding Limited (6628.HK)
HKD 0.6
(0.0%)
HKD 0.6
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -393.01 Million CNY | -17.21% |
| 2022 | -334.08 Million CNY | 80.03% |
| 2021 | -1.64 Billion CNY | -531.84% |
| 2020 | -264.81 Million CNY | 18.22% |
| 2019 | -323.81 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -56.89 Million CNY | 45.35% |
| 2024 Q2 | -56.89 Million CNY | 0.0% |
| 2023 Q1 | -115.43 Million CNY | -22.32% |
| 2023 FY | - CNY | -17.21% |
| 2023 Q4 | -104.11 Million CNY | 0.0% |
| 2023 Q3 | -104.11 Million HKD | 9.8% |
| 2023 Q2 | -115.43 Million CNY | 0.0% |
| 2022 Q2 | -102.64 Million CNY | 0.0% |
| 2022 Q1 | -102.64 Million CNY | 18.26% |
| 2022 FY | - CNY | 80.03% |
| 2022 Q4 | -94.37 Million CNY | 0.0% |
| 2022 Q3 | -94.37 Million CNY | 8.06% |
| 2021 Q3 | -125.57 Million CNY | 86.45% |
| 2021 Q4 | -125.57 Million CNY | 0.0% |
| 2021 Q2 | -926.81 Million CNY | -1187.94% |
| 2021 Q1 | -71.96 Million CNY | 33.57% |
| 2021 FY | - CNY | -531.84% |
| 2020 Q1 | -14.56 Million CNY | 0.0% |
| 2020 FY | - CNY | 18.22% |
| 2020 Q4 | -108.31 Million CNY | 0.0% |
| 2020 Q3 | -108.31 Million CNY | -26.27% |
| 2020 Q2 | -85.78 Million CNY | -488.83% |
| 2019 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 91.23 Million HKD | 530.774% |
| CK Life Sciences Int'l., (Holdings) Inc. | 486.79 Million HKD | 180.734% |